Successful Completion of ProALL-BM Clinical Trial on National Registry Group

Curewize successfully completed the clinical trial of its lead product ProALLBM on a cohort of acute lymphoblastic leukemia (ALL) patients from a European National Registry Study. ProALLBM is being produced for deciding on ALL patients risk-based treatment group, varying from standard to intense.